Pardes Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
12. September 2022 08:30 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel...
Pardes Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
15. August 2022 08:00 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug...
Pardes Biosciences to Present at Jefferies Global Healthcare Conference
01. Juni 2022 08:30 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel...
Pardes Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
10. Mai 2022 16:01 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel...
Pardes Biosciences Reports Full Year 2021 Financial Results and Provides Business Update
29. März 2022 16:05 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel...
Pardes Biosciences to Present at the International Conference On Antiviral Research 2022
21. März 2022 07:00 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif. , March 21, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel...
Pardes Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04. März 2022 16:30 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel...
Pardes Biosciences to Present at Cowen Healthcare Conference
03. März 2022 07:00 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel...
Pardes Biosciences Appoints Thomas G. Wiggans to CEO and Chairman of the Board
02. März 2022 16:30 ET
|
Pardes Biosciences, Inc
Mr. Wiggans brings over 40 years of biopharmaceutical industry experience, including over 25 years in chief executive leadership roles with multiple successful acquisitions. His expertise will be...
Pardes Biosciences Presents Interim Clinical Data from Ongoing PBI-0451 Phase 1 Trial Supporting the Potential of PBI-0451 as a Stand-Alone Oral Regimen for COVID-19 at Conference on Retroviruses and Opportunistic Infections 2022
14. Februar 2022 07:30 ET
|
Pardes Biosciences, Inc
PBI-0451 administered twice-daily as a stand-alone agent achieves and maintains PK exposures anticipated to provide potent antiviral activity against SARS-CoV-2 PBI-0451 has been generally...